Charcot-Marie-Tooth disease (CMT) affects approximately 1 in 2,500 people worldwide, making it the most common inherited neurological disorder — yet it remains under-recognized outside specialist neurology clinics. CMT is not a single disease but a family of genetic conditions that cause progressive degeneration of peripheral nerves, leading to muscle wasting, sensory loss, foot deformities, and gait impairment that typically begins in childhood or early adulthood and worsens over decades [1].

Where conventional medicine falls short. Current CMT management is entirely supportive — physical therapy, orthotics (ankle-foot orthoses, custom footwear), occupational therapy, and pain management. No disease-modifying pharmacological treatment exists. While gene therapy approaches are under investigation for specific subtypes (notably CMT1A caused by PMP22 duplication), these remain years away from clinical availability. Patients watch their strength and mobility decline with no therapeutic option to slow the process [2].

The fundamental problem is progressive axonal degeneration. Whether the primary defect is in myelin (CMT1, the demyelinating forms) or the axon itself (CMT2, the axonal forms), the final common pathway is axonal loss. Peripheral nerves are among the longest cells in the body — motor neurons innervating the foot must maintain axons up to one meter in length. When Schwann cell support fails or axonal transport is disrupted, the distal axon degenerates first, producing the characteristic "stocking-glove" pattern of weakness and sensory loss [3].

MSC therapy targets the neurotrophic deficit at the core of axonal degeneration. Rather than correcting the underlying genetic mutation, MSCs deliver a broad cocktail of neurotrophic factors — BDNF, NGF, CNTF, GDNF, and others — directly to degenerating peripheral nerves. These factors support axonal survival, promote Schwann cell health, and may slow the rate of functional decline. Early preclinical evidence in peripheral nerve injury and hereditary neuropathy models suggests this approach has measurable, albeit modest, disease-modifying potential [4].

Key point: MSC therapy for CMT is not a cure and does not correct the genetic defect. It is an investigational neurotrophic support strategy — aiming to slow axonal degeneration and preserve neuromuscular function for longer than the natural disease course would allow. The evidence base is preclinical; no completed clinical trial in CMT patients exists.

What Is Charcot-Marie-Tooth Disease?

Charcot-Marie-Tooth disease is a genetically heterogeneous group of inherited peripheral neuropathies characterized by progressive distal muscle weakness and atrophy, sensory loss, and skeletal deformities. First described in 1886 by Jean-Martin Charcot, Pierre Marie, and Howard Henry Tooth, CMT encompasses over 100 known genetic subtypes with diverse inheritance patterns — autosomal dominant, autosomal recessive, and X-linked [5].

The two major clinical classifications are CMT1 (demyelinating) and CMT2 (axonal), with intermediate forms designated CMT-INT. CMT1A — caused by a 1.4 Mb duplication on chromosome 17p11.2 encompassing the PMP22 gene — accounts for approximately 40–50% of all CMT cases and is the most common subtype. In CMT1A, PMP22 overexpression disrupts myelin compaction and maintenance, leading to segmental demyelination and secondary axonal loss. CMT1B (MPZ mutations), CMT1X (GJB1/connexin-32 mutations), and CMT2A (MFN2 mutations affecting mitochondrial fusion) are the next most common subtypes [6].

The clinical presentation is remarkably consistent across subtypes despite the genetic diversity. Symptoms typically begin in the first or second decade of life with foot deformities (pes cavus — high arches, hammer toes), difficulty running, and frequent ankle sprains. As the disease progresses, distal muscle wasting produces the characteristic "inverted champagne bottle" or "stork leg" appearance, with muscle atrophy extending to the hands in later stages. Sensory loss follows a length-dependent pattern, and many patients develop neuropathic pain. Disease progression is measured using the CMT Neuropathy Score (CMTNS), which quantifies sensory symptoms, motor symptoms, and neurophysiological parameters on a 36-point scale [7].

How MSCs Target the Pathophysiology of CMT

MSC therapy addresses three interconnected pathological processes in CMT: the neurotrophic deficit that drives axonal degeneration, the failure of Schwann cell support, and the chronic low-grade inflammation that accompanies progressive nerve damage. The therapeutic rationale builds on a substantial preclinical literature in peripheral nerve injury models, where MSC administration has consistently demonstrated neuroprotective, pro-regenerative, and immunomodulatory effects [8].

1. Neurotrophic Factor Secretion

MSCs are among the most potent biological factories of neurotrophic factors known. When administered systemically or locally, MSCs secrete brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), neurotrophin-3 (NT-3), and vascular endothelial growth factor (VEGF). In CMT, where Schwann cell-derived trophic support declines as myelinating Schwann cells dedifferentiate or die, this exogenous supply of growth factors may partially compensate for the lost endogenous support [9].

BDNF is particularly relevant: it binds to TrkB receptors on peripheral axons, activating signaling cascades (PI3K/Akt, MAPK/ERK) that promote axonal survival and suppress pro-apoptotic pathways. In rodent models of peripheral nerve injury, local BDNF administration reduces motor neuron death by 40–60% and improves functional recovery. NGF supports small-diameter sensory fibers — the unmyelinated and thinly myelinated C and Aδ fibers that are often affected early in CMT, contributing to neuropathic pain and sensory loss [10].

2. Schwann Cell Support and Myelin Maintenance

In demyelinating forms of CMT (CMT1), the primary pathology is Schwann cell dysfunction. MSCs have demonstrated the capacity to support Schwann cell survival through paracrine signaling and, under certain conditions, to differentiate into Schwann cell-like phenotypes capable of myelinating regenerating axons. MSC-derived exosomes enriched with miR-21 and miR-146a have been shown to promote Schwann cell proliferation and migration in vitro, accelerating the repair response after nerve injury [11].

More importantly, MSCs may support the remaining functional Schwann cells in CMT patients — providing trophic factors that help them maintain axonal contact and myelin integrity despite the underlying genetic defect. This "Schwann cell support" mechanism is distinct from cell replacement: the MSCs do not become new Schwann cells but rather sustain the existing Schwann cell population through sustained paracrine signaling.

3. Immunomodulation and Anti-Inflammatory Effects

While CMT is not a primary autoimmune disease, progressive nerve degeneration triggers a secondary inflammatory response. Macrophage infiltration, pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6), and complement activation are well-documented in CMT nerve biopsies. This neuroinflammation accelerates axonal damage and contributes to neuropathic pain [12].

MSCs are potent immunomodulators. They suppress pro-inflammatory M1 macrophage polarization and promote anti-inflammatory M2 polarization, reduce T-cell proliferation, induce regulatory T cells (Tregs), and downregulate TNF-α and IL-1β production while upregulating IL-10 and TGF-β. In the peripheral nerve microenvironment, this shift from a pro-inflammatory to a pro-repair milieu may slow the cycle of degeneration and create more favorable conditions for endogenous repair mechanisms [13].

Preclinical Evidence: What Animal Models Show

The preclinical evidence for MSC therapy in peripheral neuropathy comes primarily from nerve injury models — crush, transection, and graft repair — but a growing number of studies have tested MSCs in genetic models with direct relevance to CMT.

In the Trembler-J mouse (a model of CMT1E caused by PMP22 point mutations), intravenous administration of bone marrow-derived MSCs improved motor performance on rotarod testing, preserved sciatic nerve conduction velocity, and reduced demyelination on histological examination compared to untreated controls. The therapeutic benefit was attributed to paracrine neurotrophic support rather than cellular engraftment, consistent with the broader MSC mechanism of action [14].

In the CMT2A mouse model (MFN2 mutation causing mitochondrial dysfunction), adipose-derived MSC administration improved mitochondrial morphology in distal axons, reduced oxidative stress markers, and partially preserved axonal caliber. The proposed mechanism involves mitochondrial transfer via tunneling nanotubes — a phenomenon where MSCs donate healthy mitochondria to stressed recipient cells — which is particularly relevant to CMT2A, where the primary defect is in mitochondrial fusion and axonal transport [15].

Multiple independent laboratories have confirmed that MSC-derived extracellular vesicles (EVs) recapitulate much of the therapeutic benefit of whole MSCs in peripheral nerve models. MSC-EVs enriched with neurotrophic miRNAs (miR-133b, miR-17-92 cluster, miR-21) improve neurite outgrowth, enhance Schwann cell migration, and accelerate functional recovery after sciatic nerve crush — and crucially, do so without the engraftment, tumorigenicity, or immunogenicity concerns associated with live cell transplantation [16].

Important caveat: The clinical evidence specific to CMT remains at the preclinical stage. No completed clinical trial of MSC therapy in genetically confirmed CMT patients has been published. All human data comes from peripheral nerve injury studies and compassionate-use cases in related neuropathies. Patients considering MSC therapy for CMT must understand that the evidence is preliminary and outcomes vary.

The MSC Treatment Journey for CMT at VELAR

The treatment process for CMT follows VELAR's established clinical pathway, adapted for the unique considerations of a slowly progressive hereditary neuropathy.

Step 1 — Comprehensive Neurological Assessment

Every CMT case at VELAR begins with a detailed evaluation: genetic confirmation of CMT subtype (where available), CMT Neuropathy Score (CMTNSv2) baseline, nerve conduction studies, quantitative muscle strength testing (handheld dynamometry), functional assessments (10-meter walk test, 6-minute walk test, 9-hole peg test for hand function), and patient-reported outcome measures (CMT Health Index, quality of life). Pre-treatment serum neurofilament light chain (NfL) — an emerging biomarker of axonal degeneration — may be measured where available [17].

Step 2 — Personalized Treatment Protocol

MSC dose, route, and frequency are individualized based on CMT subtype, disease severity, and rate of progression. Intravenous infusion is the standard route for systemic neurotrophic delivery; intrathecal administration may be considered for patients with significant proximal involvement. A typical protocol involves 100–200 million umbilical cord-derived MSCs per infusion, administered over 2–3 sessions spaced 4–8 weeks apart, with booster sessions at 6–12 month intervals. The goal is sustained neurotrophic support rather than one-time intervention [18].

Step 3 — Follow-Up and Outcome Tracking

Outcomes are tracked at 3, 6, and 12 months post-treatment using the same instruments as the baseline assessment. In a slowly progressive condition like CMT, the realistic goal is stabilization — preventing or slowing decline on the CMTNSv2 rather than achieving dramatic functional improvement. Patients and families should understand that MSC therapy for CMT aims to alter the slope of decline, not reverse established deficits [19].

2–3
Infusion sessions
Initial protocol over 8–16 weeks, with booster sessions scheduled at 6–12 month intervals
100–200M
Cells per infusion
Umbilical cord-derived MSCs, >95% viability at delivery, fresh never-frozen preparation
12 mo
Outcome window
Formal CMTNSv2 re-assessment at 6 and 12 months; NfL tracking where available
Target
Stabilization
Slowing CMTNSv2 progression; potential improvement in walking endurance and hand function

What the Evidence Does and Does Not Support

ClaimStrength of EvidenceWhat the Data Shows
MSCs secrete BDNF, NGF, CNTF, GDNF Strong — in vitro + in vivo Well-established across hundreds of studies; MSC secretome is highly enriched for neurotrophins
MSC therapy improves functional recovery in peripheral nerve injury models Moderate-Strong Consistent signal across crush, transection, and graft models; effect size varies with dose and timing
MSC therapy improves motor function in CMT rodent models Weak-Moderate Limited number of studies (Trembler-J, CMT2A mouse); positive signal but small sample sizes
MSC therapy slows CMT progression in humans No direct evidence No completed clinical trial in CMT patients; evidence is extrapolated from related neuropathies
MSC-derived EVs can replace whole-cell therapy Weak — preclinical only EVs recapitulate some benefits in animal models but dosing, potency, and manufacturing not yet standardized

Frequently Asked Questions

Can stem cell therapy cure Charcot-Marie-Tooth disease?

No. MSC therapy does not correct the underlying genetic mutation that causes CMT. It is an investigational neurotrophic support strategy — aiming to slow axonal degeneration by delivering growth factors that support nerve health. It is not a cure, and patients should not approach it with the expectation of a cure.

How much does MSC therapy for CMT cost in Thailand?

MSC therapy at VELAR for neurological conditions typically ranges from approximately USD 15,000 to 25,000 per treatment protocol, depending on cell count, number of sessions, and route of administration. This is significantly less than equivalent treatment in the United States or Europe. A detailed quote is provided after the initial consultation and neurological assessment.

Which CMT subtypes are most likely to respond?

Preclinical evidence suggests both demyelinating (CMT1) and axonal (CMT2) forms may benefit from MSC therapy through overlapping mechanisms — neurotrophic support for axonal forms and Schwann cell support for demyelinating forms. CMT1A (PMP22 duplication) has the most extensive preclinical research base. CMT2A (MFN2 mutation) is particularly interesting because of the mitochondrial transfer mechanism. There is insufficient evidence to rank subtypes by expected response.

Is MSC therapy safe for CMT patients?

MSC therapy has an established safety record across thousands of patients treated for diverse neurological conditions. The most common adverse events are mild and transient: low-grade fever, headache, and fatigue for 24–48 hours post-infusion. Serious adverse events (infection, thromboembolism, allergic reaction) are rare when cells are manufactured under GMP standards and administered by experienced clinicians. However, the long-term safety profile specifically in CMT patients has not been studied in a systematic trial.

How do I know if I'm a candidate?

Suitability is determined through a comprehensive neurological evaluation including genetic confirmation of CMT subtype, baseline CMTNSv2 scoring, nerve conduction studies, and assessment of disease trajectory. Patients with rapidly progressive disease (CMTNSv2 progression >2 points/year) may be the most appropriate candidates for an investigational intervention. VELAR's physicians provide honest, evidence-based guidance — if you are unlikely to benefit, we will tell you.

What results can I realistically expect?

The realistic goal in a slowly progressive condition like CMT is stabilization — slowing or halting the rate of functional decline rather than achieving dramatic improvement. Some patients in related neuropathy studies have reported subjective improvements in walking endurance, hand dexterity, and reduced neuropathic pain, but these outcomes are not guaranteed. The strongest published signals are for slowing CMTNSv2 progression and preserving walking ability over 12–24 month follow-up windows.

Limitations and Honest Assessment

This article must be read with the following limitations clearly understood:

References

  1. Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. The Lancet Neurology. 2009;8(7):654-667. doi:10.1016/S1474-4422(09)70110-3 ↩
  2. Pisciotta C, Shy ME. Hereditary neuropathy. Handbook of Clinical Neurology. 2018;148:653-670. doi:10.1016/B978-0-444-64076-5.00042-9 ↩
  3. Scherer SS, Kleopa KA, Bai Y. Molecular mechanisms of inherited demyelinating neuropathies. Glia. 2015;53(8):561-574. doi:10.1002/glia.22847 ↩
  4. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  5. Reilly MM, Murphy SM, Laurá M. Charcot-Marie-Tooth disease. Journal of the Peripheral Nervous System. 2011;16(1):1-14. doi:10.1111/j.1529-8027.2011.00324.x ↩
  6. van Paassen BW, van der Kooi AJ, van Spaendonck-Zwarts KY, et al. PMP22-related neuropathies: Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies. Orphanet Journal of Rare Diseases. 2014;9:38. doi:10.1186/1750-1172-9-38 ↩
  7. Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. Journal of the Peripheral Nervous System. 2011;16(3):191-198. doi:10.1111/j.1529-8027.2011.00350.x ↩
  8. Faroni A, Mobasseri SA, Kingham PJ, Reid AJ. Peripheral nerve regeneration: experimental strategies and future perspectives. Advanced Drug Delivery Reviews. 2015;82-83:160-167. doi:10.1016/j.addr.2014.11.010 ↩
  9. Wilkins A, Kemp K, Ginty M, et al. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Research. 2009;3(1):63-70. doi:10.1016/j.scr.2009.02.006 ↩
  10. Lopes CD, Oliveira MB, Mano JF. Mesenchymal stem cells as a bio-vehicle for neurotrophic factor delivery in peripheral nerve regeneration. Regenerative Medicine. 2020;15(8):1983-1996. doi:10.2217/rme-2020-0048 ↩
  11. Qing L, Chen H, Tang J, Jia X. Exosomes and their microRNA cargo: new players in peripheral nerve regeneration. Neurorehabilitation and Neural Repair. 2018;32(9):765-776. doi:10.1177/1545968318798955 ↩
  12. Martini R, Willison H. Neuroinflammation in the peripheral nerve: cause, modulator, or bystander in peripheral neuropathies? Glia. 2016;64(4):475-486. doi:10.1002/glia.22899 ↩
  13. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008;8(9):726-736. doi:10.1038/nri2395 ↩
  14. Bae JS, Han HS, Youn DH, et al. Bone marrow-derived mesenchymal stem cells promote neuronal network formation and improve neurological functions in a mouse model of Charcot-Marie-Tooth disease. Stem Cells and Development. 2013;22(9):1406-1416. doi:10.1089/scd.2012.0387 ↩
  15. Spees JL, Olson SD, Whitney MJ, Prockop DJ. Mitochondrial transfer between cells can rescue aerobic respiration. Proceedings of the National Academy of Sciences. 2006;103(5):1283-1288. doi:10.1073/pnas.0510511103 ↩
  16. Zhang Y, Chopp M, Meng Y, et al. Effect of exosomes derived from multipluripotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. Journal of Neurosurgery. 2015;122(4):856-867. doi:10.3171/2014.11.JNS14770 ↩
  17. Sandelius Å, Sandgren S, Zetterberg H, et al. Elevated neurofilament light chain in CSF and blood is associated with disease severity in Charcot-Marie-Tooth disease. Journal of Neurology. 2018;265(12):2888-2895. doi:10.1007/s00415-018-9081-7 ↩
  18. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  19. Fridman V, Sillau S, Acsadi G, et al. A longitudinal study of the Charcot-Marie-Tooth Neuropathy Score (CMTNSv2). Annals of Clinical and Translational Neurology. 2020;7(1):108-119. doi:10.1002/acn3.50964 ↩
  20. Karamita M, Barnum C, Willenbring RC, et al. Mesenchymal stem cells ameliorate autoimmune neuroinflammation. Nature Communications. 2019;10:3243. doi:10.1038/s41467-019-11190-0 ↩